You have free access to this content

Cancer

Cover image for Vol. 119 Issue 16

15 August 2013

Volume 119, Issue 16

Pages 2947–3102

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. You have free access to this content
      Tools to improve clinical trial design in urothelial cancer (pages 2950–2952)

      Allison M. Deal and Matthew I. Milowsky

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28176

      Two reports in this issue describe a nomogram for predicting survival and a landmark analysis demonstrating the relation between 6-month and 9-month progression-free status and overall survival in patients with metastatic urothelial cancer. These 2 important tools will be used to improve future clinical trial design in patients with advanced urothelial cancer.

    2. You have free access to this content
      Prevention of human papillomavirus-related malignancy: Access is the answer (pages 2953–2955)

      Linda R. Duska and Mark H. Stoler

      Article first published online: 24 JUN 2013 | DOI: 10.1002/cncr.28180

      The majority of HPV-related cancers are caused by HPV 16 and HPV 18, but the distribution of these two viral types vary depending on race and socioeconomic status as well as the particular cancer type (cervix versus other). Ultimately, access to preventative care, including widespread pap smear screening for cervical cancer precursors and HPV vaccination, is the answer to eradicating HPV-related disease.

  3. Review Article

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. You have free access to this content
      Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? (pages 2956–2963)

      Kat Kwiatkowski, Kathryn Coe, John C. Bailar and G. Marie Swanson

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28168

      This update of a 2002 report provides evidence that diversity in the recruitment of cancer clinical trials participants has not improved in the decade since the report was published. Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the utility of cancer clinical research.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      The effects of primary care on breast cancer mortality and incidence among Medicare beneficiaries (pages 2964–2972)

      Kate J. Fisher, Ji-Hyun Lee, Jeanne M. Ferrante, Ellen P. McCarthy, Eduardo C. Gonzalez, Ren Chen, Kymia Love-Jackson and Richard G. Roetzheim

      Article first published online: 15 MAY 2013 | DOI: 10.1002/cncr.28148

      Among women who are Medicare beneficiaries, those who have 2 or more visits to a primary care physician during a 24-month interval have lower odds of breast cancer mortality, all-cause mortality, and late-stage breast cancer diagnosis compared with women who have 0 visits or 1 visit when the analysis is adjusted for other covariates, including mammography and nonprimary care physician visits. The current findings suggest that primary care physicians play an important role in reducing breast cancer mortality among this population.

    2. Gastrointestinal Disease
      You have free access to this content
      Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma (pages 2973–2980)

      Luis O. Olivatto, Fernando M. Vieira, Bruno V. Pereira, Ana P. Victorino, Marcos Bezerra, Carlos M. Araujo, Felipe Erlich, Lilian Faroni, Leonaldson Castro, Edward C. Lusis, Alessandra Marins and Carlos Gil Ferreira

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28045

      This is the first report of an anti–epidermal growth factor receptor monoclonal antibody used in combination with chemoradiation in locally advanced anal canal carcinoma. Cetuximab could not be integrated with pelvic chemoradiation based on 5-fluorouracil and cisplatin, due to the high toxicity rate.

    3. Genitourinary Disease
      You have free access to this content
      Overall survival advantage with partial nephrectomy: A bias of observational data? (pages 2981–2989)

      Brian Shuch, Janet Hanley, Julie Lai, Srinivas Vourganti, Simon P. Kim, Claude M. Setodji, Andrew W. Dick, Wong-Ho Chow, Chris Saigal and the Urologic Diseases in America Project

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28141

      Patients undergoing partial nephrectomy have improved overall survival compared with controls, suggesting that the apparent survival advantage documented in retrospective case series is the result of selection bias.

    4. You have free access to this content
      Clinical predictors of survival in men with castration-resistant prostate cancer : Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease (pages 2990–2998)

      Mari Nakabayashi, Julia Hayes, Mary-Ellen Taplin, Patrick Lefebvre, Marie-Helene Lafeuille, Mark Pomerantz, Christopher Sweeney, Mei Sheng Duh and Philip W. Kantoff

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28102

      Clinical predictors of overall survival in patients with modern castration-resistant prostate cancer (CRPC) at a large tertiary cancer center were investigated. Biopsy Gleason 6 cancer can progress to CRPC; however, it was associated with a less aggressive CRPC course.

    5. You have free access to this content
      Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria (pages 2999–3006)

      Nils Kroeger, Wanling Xie, Jae-Lyn Lee, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishamayan, Sun-Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, Min-Han Tan, Scott A. North, Brian I. Rini, Toni K. Choueiri and Daniel Y.C. Heng

      Article first published online: 21 MAY 2013 | DOI: 10.1002/cncr.28151

      The International mRCC Database Consortium risk model is a reliable prognostication tool that can be employed to prognosticate overall survival in non–clear cell renal cell carcinoma (nccRCC) for patient counseling and clinical trials design. The survival outcome for the majority of nccRCC patients remains lower than their clear-cell counterparts.

    6. You have free access to this content
      The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome (pages 3007–3011)

      Andrew J. Vickers, Daniel D. Sjoberg, Donna P. Ankerst, Catherine M. Tangen, Phyllis J. Goodman and Ian M. Thompson Jr

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28114

      The Prostate Cancer Prevention Trial risk calculator is widely used to predict the risk of prostate cancer for men considering prostate biopsy. The risk calculator is demonstrated to overestimate risk, because it assumes that the relationship between prostate-specific antigen and risk is the same for low as for elevated prostate-specific antigen levels.

    7. You have free access to this content
      Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy (pages 3012–3019)

      Matthew D. Galsky, Erin Moshier, Susan Krege, Chia-Chi Lin, Noah Hahn, Thorsten Ecke, Guru Sonpavde, James Godbold, William K. Oh and Aristotle Bamias

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28146

      Prognostic models for patients with metastatic urothelial cancer have been previously developed but not extensively validated or expanded on. The current nomogram, which was validated both internally and externally, facilitates individualized prognostic estimates with moderate discrimination.

    8. You have free access to this content
      Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy (pages 3020–3026)

      Matthew D. Galsky, Susan Krege, Chia-Chi Lin, Noah Hahn, Thorsten Ecke, Erin Moshier, Guru Sonpavde, James Godbold, William K. Oh and Aristotle Bamias

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28145

      Response rate has traditionally been used as the primary endpoint of phase 2 trials in metastatic urothelial cancer but may be problematic in screening the activity of novel combination regimens. The current analysis demonstrates that progression-free survival, measured at fixed time points, is highly correlated with overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy and may be a more attractive intermediate endpoint in this clinical disease state.

    9. Gynecologic Oncology
      You have free access to this content
      Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome (pages 3027–3033)

      Marilyn Huang, Bojana Djordjevic, Melinda S. Yates, Diana Urbauer, Charlotte Sun, Jennifer Burzawa, Molly Daniels, Shannon N. Westin, Russell Broaddus and Karen Lu

      Article first published online: 12 JUN 2013 | DOI: 10.1002/cncr.28152

      Hyperplasia is part of the preinvasive spectrum of disease in Lynch syndrome (LS)-associated endometrial cancer (EC), as indicated by the presence of concurrent complex hyperplasia and complex atypical hyperplasia in cases of LS-associated EC cases. Although loss of phosphatase and tensin homolog is common in both LS and sporadic EC cases, there was a lack of additional mutations noted in LS-associated EC, suggesting that within the context of the mismatch repair defects in LS, fewer additional molecular changes are required to progress from preinvasive lesions to carcinoma.

    10. Head and Neck Disease
      You have free access to this content
      High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma (pages 3034–3042)

      Edmund A. Mroz, Aaron D. Tward, Curtis R. Pickering, Jeffrey N. Myers, Robert L. Ferris and James W. Rocco

      Article first published online: 20 MAY 2013 | DOI: 10.1002/cncr.28150

      Higher intratumor genetic heterogeneity was associated with shorter overall survival among patients with head and neck squamous cell carcinoma, particularly for those receiving chemotherapy. The quantitative measure of heterogeneity used in the current study, based on next-generation genomic DNA sequencing, can be evaluated similarly in other combinations of cancers and therapies to test the long-standing hypothesis that highly heterogeneous tumors contribute to poor patient outcomes.

    11. Discipline

      Clinical Trials
      You have free access to this content
      Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation (pages 3043–3051)

      Eunice L. Kwak, Geoffrey I. Shapiro, Seth M. Cohen, Carlos R. Becerra, Heinz-Josef Lenz, Wen-Fang Cheng, Wu-Chou Su, Meghan Robohn, Florence Le Maulf, Maximilian T. Lobmeyer, Vikram K. Chand and A. John Iafrate

      Article first published online: 14 JUN 2013 | DOI: 10.1002/cncr.28120

      In this phase 2, open-label, exploratory trial, single-agent afatinib, an irreversible ErbB Family Blocker, demonstrates limited yet encouraging activity with manageable tolerability in multiple histologies of solid tumors (excluding lung cancer) in patients who were screened prospectively for EGFR/HER2 gene amplification or EGFR-activating mutations. The early termination of this study because of recruitment challenges highlights the need for alternative approaches in biomarker-driven patient selection in this setting.

    12. Disparities Research
      You have free access to this content
      Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty (pages 3052–3058)

      Linda M. Niccolai, Chelsea Russ, Pamela J. Julian, Susan Hariri, John Sinard, James I. Meek, Vanessa McBride, Lauri E. Markowitz, Elizabeth R. Unger, James L. Hadler and Lynn E. Sosa

      Article first published online: 9 MAY 2013 | DOI: 10.1002/cncr.28038

      Black race, Hispanic ethnicity, and higher area-based poverty are salient predictors of lower human papillomavirus 16/18 positivity among women with high-grade cervical lesions. These findings have implications for vaccine impact monitoring, vaccination programs, and new vaccine development.

    13. You have free access to this content
      Evaluation of a patient navigation program to promote colorectal cancer screening in rural Georgia, USA (pages 3059–3066)

      Sally Honeycutt, Rhonda Green, Denise Ballard, April Hermstad, Alex Brueder, Regine Haardörfer, Jennifer Yam and Kimberly J. Arriola

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28033

      Patients at federally qualified community health centers with a patient navigation program to reduce barriers to colorectal cancer screening were significantly more likely to undergo colonoscopy screening and be guideline-compliant on at least one colorectal cancer screening test than patients at comparison clinics. Patient navigation can be an effective approach to ensure that preventive health screenings are provided to low-income adults in a rural setting.

    14. You have free access to this content
      Treatment of early-stage prostate cancer among rural and urban patients (pages 3067–3075)

      Laura-Mae Baldwin, C. Holly A. Andrilla, Michael P. Porter, Roger A. Rosenblatt, Shilpen Patel and Mark P. Doescher

      Article first published online: 13 JUN 2013 | DOI: 10.1002/cncr.28037

      Between 2004 and 2006, this adjusted analysis found that men who were living in rural areas were less likely to receive definitive treatment for their early-stage prostate cancer than those living in urban areas. Providers, rural health care systems, and cancer advocacy and support organizations should ensure resources are in place so the most vulnerable rural groups (men between 60 and 74 years of age; African American men; men who are single, separated, or divorced; and men living in rural New Mexico) can make informed prostate cancer treatment choices based on their preferences.

    15. Medical Oncology
      You have free access to this content
      Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity (pages 3076–3083)

      Chirayu Patel, Leif Stenke, Sudhir Varma, Marita Lagergren Lindberg, Magnus Björkholm, Jan Sjöberg, Kristina Viktorsson, Rolf Lewensohn, Ola Landgren, Michael M. Gottesman and Jean-Pierre Gillet

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28098

      Analysis of paired samples taken at diagnosis and after relapse from a group of leukemia patients with drug-resistant cancer revealed that each patient had a unique gene signature representing different mechanisms of resistance. The data underline the need for personalized molecular analysis in order to design specific treatments suitable for individual patients with acute myeloid leukemia.

    16. You have free access to this content
      Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location (pages 3084–3091)

      Talia Golan, Damien Urban, Raanan Berger and Yaacov Richard Lawrence

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28143

      The overall survival of patients with newly diagnosed metastatic colon cancer in the United States markedly improved from 1988–2008, especially for left-sided tumors. However, little improvement was seen in patients over 70 years of age.

    17. Outcomes Research
      You have free access to this content
      Applicability of randomized trials in radiation oncology to standard clinical practice (pages 3092–3099)

      Smith Apisarnthanarax, Samuel Swisher-McClure, Wing K. Chiu, Randall J. Kimple, Stephen L. Harris, David E. Morris and Joel E. Tepper

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28149

      A significant proportion of medical decisions are made without available or applicable randomized evidence to inform radiotherapeutic medical decision making in an academic radiation oncology clinic. These findings underscore the limitations of relying solely on prospective randomized controlled trials for the development of evidence-based health care.

  5. Correspondences

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
  6. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Article
    5. Original Articles
    6. Correspondences
    7. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION